Clinical Trials

Targeted Therapeutics for Cancer and Ophthalmology

TRC105
  • Recruiting
  • Recruiting
  • Ongoing, not recruiting
  • Recruiting
  • Recruiting
  • Recruiting
  • Ongoing, not recruiting
  • Ongoing, not recruiting
  • Completed
  • Completed
  • Completed
  • Completed
  • Completed

TUMOR TYPE

  • Kidney Cancer
  • Glioblastoma
  • Glioblastoma
  • Advanced Renal Cell Cancer
  • Advanced Soft Tissue Sarcoma
  • Liver Cancer
  • Liver Cancer
  • Metastatic Breast Cancer
  • Advanced Solid Tumors
  • Prostate Cancer
  • Urothelial Carcinoma
  • Ovarian Cancer
  • Advanced or Metastatic Solid Tumors

STUDY

  • Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
  • Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
  • A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
  • A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
  • A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
  • Sorafenib and TRC105 in Hepatocellular Cancer
  • TRC105 for Liver Cancer That Has Not Responded to Sorafenib
  • Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
  • Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
  • A Phase 1/2 Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
  • TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
  • Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
  • Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

PHASE

  • Ph 2b randomized
  • Ph 1b/2b randomized
  • Ph 2a
  • Ph 1b
  • Ph 1b
  • Ph 1b/2a
  • Ph 2a
  • Ph 1b
  • Ph 1b
  • Ph 1/2
  • Ph 2a
  • Ph 2a
  • Ph 1

AGENT(S)

  • TRC105 + Avastin® (bevacizumab)
  • TRC105 + Avastin® (bevacizumab)
  • TRC105 + Avastin® (bevacizumab)
  • TRC105 + Inlyta® (axinitib)
  • TRC105 + Votrient® (Pazopanib)
  • TRC105 + Nexavar® (sorafenib)
  • TRC105
  • TRC105 + Xeloda® (capecitabine)
  • TRC105 + Avastin® (bevacizumab)
  • TRC105
  • TRC105
  • TRC105
  • TRC105
TRC102
  • Recruiting
  • Recruiting
  • Recruiting
  • Completed

TUMOR TYPE

  • Solid tumors and Lymphomas
  • Hematologic Cancer
  • Advanced or Metastatic Solid Tumors
  • Advanced or Metastatic Solid Tumors

STUDY

  • TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
  • Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
  • Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
  • Study of TRC102 in Combination With Pemetrexed in Cancer Patients

PHASE

  • Ph 1b
  • Ph 1b
  • Ph 1
  • Ph 1b

AGENT(S)

  • TRC102 + Temodar® (temozolomide)/li>
  • TRC102 + Fludara® (fludarabine)
  • TRC102 + Temodar® (temozolomide)
  • TRC102 + Alimta® (pemetrexed)